Heart Transplantation
📧 Sign up to get email alerts when something new happens for Heart Transplantation.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2015-11-13FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for a generic version of mycophenolate mofetil from Hikma Pharmaceuticals USA Inc. The drug is u…
-
FDA label_change · 2015-10-30FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA supplemental application for mycophenolate mofetil filed by Hikma Pharmaceuticals USA Inc. to update the product labeling.
-
FDA approval · 2015-09-28FDA Approved: TACROLIMUS — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for tacrolimus by Accord Healthcare Inc., expanding the availability of a generic tacrolimus product…
-
FDA approval · 2015-08-04FDA Approved: MYFORTIC — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for MYFORTIC (mycophenolic acid) from Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2015-06-16Clinical Trial Update: Study to Compare the Pharmacokinetics of Tacrolimus in Adult Transplant Recipients Treated With Advagraf® or Prograf® [Phase 2]
A Phase 2 study comparing tacrolimus pharmacokinetics in adult heart, lung, and pancreas transplant recipients treated with Advagraf vs Prog…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-05-28FDA Approved: SIROLIMUS — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for sirolimus submitted by Mylan Pharmaceuticals, granting regulatory approval for changes to th…
-
CLINICAL_TRIALS trial_result · 2015-05-28Clinical Trial Update: Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients [Phase 4]
Phase 4 study comparing lower immunosuppression versus traditional immunosuppression in heart transplant recipients to evaluate safety outco…
-
CLINICAL_TRIALS trial_result · 2014-10-29Clinical Trial Update: A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients. [Phase 3]
A Phase 3 trial evaluating CellCept (mycophenolate mofetil) in combination therapy for heart transplant patients has completed, with results…
-
FDA approval · 2014-07-22FDA Approved: TACROLIMUS — Original Application (Strides Pharma Science Limited)
FDA approved Strides Pharma Science Limited's tacrolimus original application, enabling a generic tacrolimus product for prevention of organ…
-
CLINICAL_TRIALS trial_result · 2014-05-13Clinical Trial Update: SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance [Phase 4]
Phase 4 update on the SCHEDULE trial evaluating de novo everolimus with early calcineurin inhibitor avoidance in heart transplant recipients…
-
FDA approval · 2013-09-27FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for CELLCEPT (mycophenolate mofetil) submitted by Genentech, Inc.
-
FDA approval · 2013-09-27FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for a generic mycophenolate mofetil product from Strides Pharma Science Limited, enabling its market…
-
FDA approval · 2013-09-04FDA Approved: PROGRAF — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for PROGRAF (tacrolimus) submitted by Astellas Pharma US, Inc. The action relates to an update o…
-
FDA approval · 2013-08-16FDA Approved: PROGRAF — Supplemental Application (Astellas Pharma US, Inc.)
FDA approves a supplemental application for PROGRAF (tacrolimus) filed by Astellas Pharma US, approving changes to the product labeling.
-
FDA approval · 2013-07-19FDA Approved: ASTAGRAF XL — Original Application (Astellas Pharma US, Inc.)
FDA approved ASTAGRAF XL (tacrolimus extended-release capsules) under an Original Application from Astellas Pharma US. It provides a new tac…
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
This completed clinical trial from NIAID examined how donor and recipient genetic expression influences survival after heart, lung, liver, a…
-
CLINICAL_TRIALS trial_result · 2013-02-20Clinical Trial Update: Effect of Exercise After Heart Transplantation [Phase 2]
A Phase 2 clinical trial evaluating the effects of an exercise program after heart transplantation has completed.
-
CLINICAL_TRIALS trial_result · 2013-01-04Clinical Trial Update: Study on Heart Rate Variability in Cardiac Transplant Recipients With Exercise and After Exercise Training [NA]
A completed clinical trial, sponsored by National Taiwan University Hospital, evaluating heart rate variability in heart transplant recipien…
-
FDA approval · 2012-12-10FDA Approved: TACROLIMUS — Supplemental Application (Sandoz Inc.)
FDA approved a supplemental application for tacrolimus from Sandoz Inc., updating labeling related to its use in preventing organ transplant…
-
CLINICAL_TRIALS research · 2012-10-16Clinical Trial Update: Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement [NA]
Update on a clinical study investigating whether a bedside exercise device and activity reinforcement improve rehabilitation after heart tra…
-
FDA approval · 2012-09-25FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approves a supplemental application for mycophenolate mofetil, the generic immunosuppressant, via Teva Pharmaceuticals USA, Inc. This ac…
-
FDA approval · 2012-08-31FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Strides Pharma Science Limited)
The FDA approved a supplemental application for mycophenolate mofetil from Strides Pharma Science Limited. This approval supports continued …
-
FDA approval · 2012-08-29FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application to allow Strides Pharma Science Limited to market a generic version of mycophenolate mofetil.
-
FDA approval · 2012-06-08FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for CELLCEPT (mycophenolate mofetil) submitted by Genentech, Inc.
-
FDA approval · 2012-02-06FDA Approved: PROGRAF — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for PROGRAF (tacrolimus) from Astellas Pharma US, Inc., updating its label to cover transplant-r…